Despite finding pro-inflammatory activation of TAMs, we found that PD-L1 blockade alone was not sufficient to control tumor growth in vivo and anti-PD-1 was still needed to promote the CD8+ T cell response and effective tumor control. The gene discussed is CD8A; the disease is neoplasm.